Both systems received U.S. Food and Drug Administration clearance earlier this spring and were unveiled at the recent American College of Obstetricians and Gynecologists annual meeting in San Diego, Calif.
“With the introduction of the HS50 and HS60, Samsung is able to bring the exceptional image quality and penetration that our high-end customers have come to expect and rely on to a wider audience,” said Phil Sullivan, president and CEO for Samsung NeuroLogica. “With its smaller footprint and affordability, it will allow more clinicians to provide their patients the very best of care.”
The HS50 and HS60 feature hybrid beamformer technology that works in conjunction with Samsung’s advanced Digital Signal Processing to provide clear, detailed images that help clinicians diagnose and care for their patients. Advanced 3D/4D technologies provide additional diagnostic views to help support clinical decision making and treatment planning, and workflow enhancing and time-saving tools allow the clinician to focus more on their patients instead of the system. The capabilities of the HS50 and HS60 make them a great fit for many different practice types, including obstetrics and gynecology, general imaging and MSK.
Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co. Ltd., develops, manufactures, and markets imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. Samsung NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the U.S. headquarters for sales, marketing, and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s portfolio of advanced medical technologies are used worldwide in healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency.